IL-22 has been shown to activate STAT3 and promote epithelial recovery in experimental GVHD models (22, 34), and it has recently been investigated in a clinical trial for the treatment of newly diagnosed GI GVHD along with systemic CS (35). Here, STAT3 is linked to Cowden syndrome 1.